ANXA1 can reduce leukocyte adhesion to endothelial cells and have microvascular‐protective effects in the context of metabolic syndrome.[15] Collectively, this evidence suggests that ANXA1 might have therapeutic potential in cardiovascular disorders. Here, ANXA1 is linked to metabolic syndrome.